Why the study?
Diabetic cardiomyopathy has a multifaceted pathogenesis, and the mechanism of action of Zhilong Huoxue Tongyu Capsule in this condition was not fully understood.
Does Zhilong Huoxue Tongyu Capsule mitigate myocardial fibrosis and alter protein expression in a mouse model of diabetic cardiomyopathy?
Population
DCM model mice
Comparison
Zhilong Huoxue Tongyu capsule vs SB203580 vs rosiglitazone vs physiological saline control
Design
Animal experimental study with network pharmacology analysis
Follow-up
6 weeks
Key result
Zhilong Huoxue Tongyu Capsule significantly mitigated myocardial fibrosis and down-regulated p-P38MAPK, TNF-α, α-SMA, and Collagen-I proteins in a mouse model of diabetic cardiomyopathy.
Authors
Loading...
Hypothesis-generating in diabetic cardiomyopathy mice; should not change clinical practice pending human data.
Does Zhilong Huoxue Tongyu Capsule mitigate myocardial fibrosis and alter protein expression in a mouse model of diabetic cardiomyopathy?
Zhilong Huoxue Tongyu Capsule ameliorates diabetic cardiomyopathy in mice, likely by modulating the P38MAPK signaling pathway.
Yang et al. (2025) studied Diabetic cardiomyopathy. Zhilong Huoxue Tongyu Capsule (ZL) vs. Physiological saline, SB203580, and rosiglitazone was evaluated on Myocardial fibrosis and expression of p-P38MAPK, TNF-α, α-SMA, and Collagen-I proteins. Zhilong Huoxue Tongyu Capsule significantly mitigated myocardial fibrosis and down-regulated p-P38MAPK, TNF-α, α-SMA, and Collagen-I proteins in a mouse model of diabetic cardiomyopathy.